Oral osteonecrosis associated with the use of ibandronate

report of a case and clinical implications

Cesar Migliorati, Basil N. Armonis, Ourania Nicolatou-Galitis

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A breast cancer patient with skeletal metastases was treated with only one IV dose of ibandronate in March of 2005 and subsequent doses of oral ibandronate 50 mg daily. One year after the IV infusion, the patient complained of oral pain under her lower denture. After several negative attempts from her dentist to control the pain and adjust the denture, the patient was diagnosed with bisphosphonate-associated osteonecrosis (BON) of the mandible. The use of ibandronate, a potent bisphosphonate, is increasing worldwide. Prescribing oncologists should be aware of the potential for the developement of new cases of BON in a similar fashion as with zoledronic acid.

Original languageEnglish (US)
JournalOral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology
Volume106
Issue number1
DOIs
StatePublished - Jul 1 2008

Fingerprint

Osteonecrosis
Bisphosphonate-Associated Osteonecrosis of the Jaw
zoledronic acid
Dentures
Pain
Diphosphonates
Dentists
Mandible
Breast Neoplasms
Neoplasm Metastasis
ibandronic acid

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology
  • Surgery
  • Dentistry(all)
  • Oral Surgery

Cite this

Oral osteonecrosis associated with the use of ibandronate : report of a case and clinical implications. / Migliorati, Cesar; Armonis, Basil N.; Nicolatou-Galitis, Ourania.

In: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, Vol. 106, No. 1, 01.07.2008.

Research output: Contribution to journalArticle

@article{170bbdc2e4e344729fb77471f9ff590a,
title = "Oral osteonecrosis associated with the use of ibandronate: report of a case and clinical implications",
abstract = "A breast cancer patient with skeletal metastases was treated with only one IV dose of ibandronate in March of 2005 and subsequent doses of oral ibandronate 50 mg daily. One year after the IV infusion, the patient complained of oral pain under her lower denture. After several negative attempts from her dentist to control the pain and adjust the denture, the patient was diagnosed with bisphosphonate-associated osteonecrosis (BON) of the mandible. The use of ibandronate, a potent bisphosphonate, is increasing worldwide. Prescribing oncologists should be aware of the potential for the developement of new cases of BON in a similar fashion as with zoledronic acid.",
author = "Cesar Migliorati and Armonis, {Basil N.} and Ourania Nicolatou-Galitis",
year = "2008",
month = "7",
day = "1",
doi = "10.1016/j.tripleo.2008.03.005",
language = "English (US)",
volume = "106",
journal = "Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology",
issn = "2212-4403",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Oral osteonecrosis associated with the use of ibandronate

T2 - report of a case and clinical implications

AU - Migliorati, Cesar

AU - Armonis, Basil N.

AU - Nicolatou-Galitis, Ourania

PY - 2008/7/1

Y1 - 2008/7/1

N2 - A breast cancer patient with skeletal metastases was treated with only one IV dose of ibandronate in March of 2005 and subsequent doses of oral ibandronate 50 mg daily. One year after the IV infusion, the patient complained of oral pain under her lower denture. After several negative attempts from her dentist to control the pain and adjust the denture, the patient was diagnosed with bisphosphonate-associated osteonecrosis (BON) of the mandible. The use of ibandronate, a potent bisphosphonate, is increasing worldwide. Prescribing oncologists should be aware of the potential for the developement of new cases of BON in a similar fashion as with zoledronic acid.

AB - A breast cancer patient with skeletal metastases was treated with only one IV dose of ibandronate in March of 2005 and subsequent doses of oral ibandronate 50 mg daily. One year after the IV infusion, the patient complained of oral pain under her lower denture. After several negative attempts from her dentist to control the pain and adjust the denture, the patient was diagnosed with bisphosphonate-associated osteonecrosis (BON) of the mandible. The use of ibandronate, a potent bisphosphonate, is increasing worldwide. Prescribing oncologists should be aware of the potential for the developement of new cases of BON in a similar fashion as with zoledronic acid.

UR - http://www.scopus.com/inward/record.url?scp=46149108856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46149108856&partnerID=8YFLogxK

U2 - 10.1016/j.tripleo.2008.03.005

DO - 10.1016/j.tripleo.2008.03.005

M3 - Article

VL - 106

JO - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

JF - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

SN - 2212-4403

IS - 1

ER -